StreetInsider.com News Articles

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

Mon, 03 Aug 2026 12:01:00 -0400

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without changes to the current protocol.
The recommendation followed the IDMC’s review of the complete safety and efficacy dataset for an interim analysis in 30 patients.
Based on unblinded data, a futility analysis indicated sufficient probability of achieving the primary endpoint—based on differences in PET/CT imaging—and selected secondary endpoints.
Preliminary biomarker analysis of blinded data showed inflammatory biomarker trends consistent with OATD-01's expected biological response.
Molecure is

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

Mon, 03 Aug 2026 12:01:00 -0400

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without changes to the current protocol.
The recommendation followed the IDMC’s review of the complete safety and efficacy dataset for an interim analysis in 30 patients.
Based on unblinded data, a futility analysis indicated sufficient probability of achieving the primary endpoint—based on differences in PET/CT imaging—and selected secondary endpoints.
Preliminary biomarker analysis of blinded data showed inflammatory biomarker trends consistent with OATD-01's expected biological response.
Molecure is

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

Mon, 03 Aug 2026 12:01:00 -0400

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without changes to the current protocol.
The recommendation followed the IDMC’s review of the complete safety and efficacy dataset for an interim analysis in 30 patients.
Based on unblinded data, a futility analysis indicated sufficient probability of achieving the primary endpoint—based on differences in PET/CT imaging—and selected secondary endpoints.
Preliminary biomarker analysis of blinded data showed inflammatory biomarker trends consistent with OATD-01's expected biological response.
Molecure is

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

Mon, 03 Aug 2026 12:01:00 -0400

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without changes to the current protocol.
The recommendation followed the IDMC’s review of the complete safety and efficacy dataset for an interim analysis in 30 patients.
Based on unblinded data, a futility analysis indicated sufficient probability of achieving the primary endpoint—based on differences in PET/CT imaging—and selected secondary endpoints.
Preliminary biomarker analysis of blinded data showed inflammatory biomarker trends consistent with OATD-01's expected biological response.
Molecure is

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research